NASDAQ · Financial Statements

CASI Pharmaceuticals, Inc. (CASI) Financial Statements

$0.15 NASDAQ: CASI Market Cap $2.33M

CASI Pharmaceuticals, Inc. most recently reported annual revenue of $29.0M, a net loss of $39.0M. Revenue grew at an average annual rate of 48.6% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

CASI Pharmaceuticals, Inc.: net profit was positive in 0 of 10 reported years; operating margin moved from 14990.8% to -138.8%, a shift of -15129.6 percentage points; the most recent year shows a net loss of $39.0M.

Income Statement — 10 Years (USD millions)

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue	$0	$0	$0	$0	$4.0M	$15.0M	$30.0M	$43.0M	$34.0M	$29.0M
Operating Expenses	$-7.0M	$-9.0M	$11.0M	$27.0M	$44.0M	$68.0M	$72.0M	$70.0M	$59.0M	$68.0M
Operating Profit	$7.0M	$9.0M	$-11.0M	$-27.0M	$-40.0M	$-53.0M	$-42.0M	$-26.0M	$-25.0M	$-40.0M
Operating Margin	14990.8%	0.0%	0.0%	0.0%	-968.1%	-348.6%	-137.6%	-61.5%	-74.0%	-138.8%
Other Income	$0	$0	$0	$-1.0M	$-5.0M	$5.0M	$6.0M	$-12.0M	$-1.0M	$2.0M
Interest	$0	$0	$0	$0	$0	$0	$0	$0	$0	$1.0M
Depreciation	$0	$0	$0	$2.0M	$2.0M	$2.0M	$2.0M	$2.0M	$4.0M	$2.0M
Profit Before Tax	$-7.0M	$-9.0M	$-11.0M	$-27.0M	$-45.0M	$-48.0M	$-36.0M	$-38.0M	$-26.0M	$-38.0M
Tax	$-1.1M	$-360,000	$-140,000	$0	$0	$0	$0	$-5.2M	$310,000	$-3.1M
Net Profit	$-7.0M	$-9.0M	$-11.0M	$-27.0M	$-45.0M	$-48.0M	$-37.0M	$-41.0M	$-27.0M	$-39.0M
EPS	$-2.22	$-1.69	$-1.75	$-3.24	$-4.80	$-4.37	$-2.69	$-3.01	$-2.02	$-2.56
Dividend Payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

Metric	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25
Revenue	$15.0M	$8.0M	$10.0M	$9.0M	$7.0M	$3.0M	$4.0M	$8.0M	$13.0M	$6.0M	$4.0M	$3.0M
Operating Expenses	$28.0M	$16.0M	$18.0M	$14.0M	$12.0M	$13.0M	$13.0M	$16.0M	$26.0M	$17.0M	$15.0M	$14.0M
Operating Profit	$-13.0M	$-7.0M	$-8.0M	$-5.0M	$-5.0M	$-9.0M	$-9.0M	$-8.0M	$-13.0M	$-10.0M	$-11.0M	$-11.0M
Operating Margin	-82.8%	-86.4%	-81.9%	-57.6%	-68.8%	-270.4%	-220.9%	-108.6%	-96.7%	-166.3%	-266.5%	-347.2%
Interest	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Profit Before Tax	$-17.0M	$-6.0M	$-10.0M	$-4.0M	$-6.0M	$-10.0M	$-7.0M	$-7.0M	$-14.0M	$-11.0M	$-11.0M	$-11.0M
Tax	$-11.4M	$0	$790,000	$0	$20,000	$0	$0	$-15.3M	$0	$0	$-19.4M	$0
Net Profit	$-20.0M	$-6.0M	$-10.0M	$-5.0M	$-6.0M	$-10.0M	$-7.0M	$-8.0M	$-14.0M	$-11.0M	$-13.0M	$-11.0M
EPS	$-1.45	$-0.45	$-0.77	$-0.35	$-0.45	$-0.71	$-0.52	$-0.55	$-0.93	$-0.69	$-0.86	$-0.68

Over the 10 years reported for CASI Pharmaceuticals, Inc., borrowings increased from $1.0M in 2015 to $22.0M in 2024, cash stood at $13.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.11 times.

Balance Sheet — 10 Years (USD millions)

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	$6.0M	$28.0M	$45.0M	$113.0M	$103.0M	$128.0M	$138.0M	$96.0M	$75.0M	$54.0M
Current Assets	$6.0M	$27.0M	$44.0M	$93.0M	$62.0M	$74.0M	$62.0M	$73.0M	$59.0M	$40.0M
Cash	$5.0M	$27.0M	$43.0M	$84.0M	$54.0M	$57.0M	$39.0M	$47.0M	$17.0M	$13.0M
Inventory	$0	$0	$0	$0	$5.0M	$1.0M	$2.0M	$6.0M	$16.0M	$5.0M
Receivables	$0	$0	$0	$0	$1.0M	$5.0M	$10.0M	$13.0M	$10.0M	$15.0M
Fixed Assets	$0	$0	$1.0M	$2.0M	$10.0M	$11.0M	$22.0M	$13.0M	$12.0M	$11.0M
Capital Work in Progress	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Investments	$0	$0	$0	$1.0M	$15.0M	$39.0M	$50.0M	$12.0M	$15.0M	$4.0M
Other Assets	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$12.0M	$7.0M	$7.0M	$4.0M	$9.0M	$24.0M	$30.0M	$29.0M	$51.0M	$52.0M
Current Liabilities	$1.0M	$1.0M	$5.0M	$4.0M	$8.0M	$8.0M	$13.0M	$17.0M	$17.0M	$36.0M
Borrowings	$1.0M	$1.0M	$1.0M	$1.0M	$2.0M	$3.0M	$4.0M	$1.0M	$21.0M	$22.0M
Other Liabilities	$10.0M	$5.0M	$5.0M	$2.0M	$7.0M	$21.0M	$26.0M	$28.0M	$30.0M	$30.0M
Equity	$0	$1.0M	$1.0M	$1.0M	$1.0M	$1.0M	$1.0M	$0	$0	$0
Reserves	$-6.0M	$21.0M	$39.0M	$109.0M	$73.0M	$82.0M	$85.0M	$45.0M	$24.0M	$2.0M

For CASI Pharmaceuticals, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $29.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Operating Cash Flow	$-6.0M	$-6.0M	$-6.0M	$-29.0M	$-23.0M	$-26.0M	$-27.0M	$-21.0M	$-20.0M	$-29.0M
Investing Cash Flow	$0	$0	$-2.0M	$-44.0M	$-42.0M	$-40.0M	$-36.0M	$26.0M	$-12.0M	$11.0M
Financing Cash Flow	$0	$0	$0	$4.0M	$23.0M	$1.0M	$-2.0M	$-3.0M	$0	$1.0M
Net Cash Flow	$-6.0M	$22.0M	$16.0M	$41.0M	$-31.0M	$3.0M	$-18.0M	$8.0M	$-30.0M	$-4.0M
Free Cash Flow	$-6.0M	$-6.0M	$-7.0M	$-50.0M	$-37.0M	$-45.0M	$-42.0M	$-27.0M	$-22.0M	$-29.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.54
FCF Yield	0.00%
Quick Ratio	0.24
Interest Coverage	-50.60
Return 1Y	—
Return 3Y	—
Return 5Y	—

CASI Pharmaceuticals, Inc. (CASI) financials — frequently asked questions

What is CASI Pharmaceuticals, Inc.'s annual revenue?

CASI Pharmaceuticals, Inc. (CASI) reported annual revenue of $29.0M in its most recent fiscal year.

What is CASI Pharmaceuticals, Inc.'s net profit?

CASI Pharmaceuticals, Inc. (CASI) reported a net loss of $39.0M in its most recent fiscal year.

What is CASI EV/EBITDA?

CASI Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.54. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

CASI Overview CASI Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.